- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03186001
Frontalis Botulinum Toxin
The Impact of Botulinum Toxin Injection in the Frontalis on Brow Height and Morphology: A Randomized Trial
Study Overview
Detailed Description
Botulinum toxin:
This toxin has been used clinically since 1989 with label (8) and off-label techniques(3).
This is a becoming a routine procedure for men and women with little side effects.
Brow lifting The ideal brow position is always an issue in plastic surgery(12). When face ages, the brow descends. Many approaches to a brow elevation are described in the literature. The first surgical approach is through a coronal incision(13), then came the temporal incision(14) and the direct approach(15), and finally the endoscopic approach(16). Non-surgical methods include radiofrequency(17), percutaneous sutures and botulinum toxin(11).
Standardized measure Anteroposterior pictures will be taken at rest pre and post injection. Using photoshop 7 brow landmarks will be measured to the midpupillary line.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beirut, Lebanon, 0000
- Saint Joseph University
-
Contact:
- joseph el khoury, M.D.
- Phone Number: 00961 70745258
- Email: drjosephelkhoury@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consecutive 30 female patients presenting to our clinic for brow lifting with botulinum toxin will be randomized to receive one of the two injection techniques
- 30 Years to 60 Years
- Female
Exclusion Criteria:
- Patients with previous periorbital/forehead surgery
- Patients who plucked the upper eyebrow margin
- Patients with eyebrow tatoos
- Patients with upper face botulinum toxin injection in the past 12 months
- Patients with resorbable upper face fillers injection in the past 12 months
- Patients with previous permanent upper face fillers injection
- Pregnant patients
- Lactating patients
- Patients with preexisting neuromuscular conditions (myasthenia gravis, Eaton Lambert syndrome)
- Patients using medication that could potentiate the effect of botulinum (ex: aminoglycoside antibiotics)
- Patients with sensitivity to botulinum toxin or human albumin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: v shape
Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.
Then 5 equally spaced injections, in a V pattern will be placed in the frontalis.
The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
|
The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection.
It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
|
Experimental: middle frontalis
: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.
Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis.
One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
|
The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection.
It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
|
Experimental: high frontalis
: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis.
One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
|
The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection.
It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective assessment
Time Frame: 2 weeks
|
Objective assessment will be done on anteroposterior views of pre-and-post injection photographs.
The mid pupillary line will be drawn and the eyebrow vertical height will be measured from this line to the upper border of the brow at seven horizontal points: the most medial aspect of the eyebrow, medial canthus, and medial limbus, mid pupil, lateral limbus, lateral canthus, and most lateral eyebrow.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-Investigators Global Aesthetic Improvement Scale
Time Frame: 2 weeks
|
Improvement in Overall appearance of the upper face, as assessed by the 3 investigators (2 plastic surgeons and 1 dermatologist) using the Global Aesthetic Improvement Scale (GAIS). GAIS will be completed based on photographic assessment comparing post-treatment photos taken at day 15 post intervention to baseline photos (the lower eyelids and lower face will be cropped), to assess overall aesthetic improvement. The GAIS is a 5-point scale (1-5) as follows:
|
2 weeks
|
2-Patient satisfaction
Time Frame: 2 weeks
|
Patient satisfaction will be determined by a questionnaire completed at 15 days post-treatment. Subjects will indicate how satisfied they are on a 4-point scale (1-4) as follow:
|
2 weeks
|
3-Brow Positioning Scale
Time Frame: 2 weeks
|
subjective evaluation using a photonumeric validated scale for eye brow positioning (evaluated by 2 plastic surgeons and 1 dermatologist) using pre and post injection photographs (taken at day 15 and 30) as follow: 0-Youthful, refreshed look and high-arch eyebrow
|
2 weeks
|
4-Forehead Lines Scale:
Time Frame: 2 weeks
|
subjective evaluation using a photonumeric validated scale for forehead lines at rest (evaluated by 2 plastic surgeons and 1 dermatologist) using pre and post injection photographs (taken at day 15 and 30) as follow: 0-None
|
2 weeks
|
5-Glabellar Lines Scale
Time Frame: 2 weeks
|
subjective evaluation using a photonumeric validated scale for glabella lines at rest (evaluated by 2 plastic surgeons and 1 dermatologist) using pre and post injection photographs (taken at day 15) as follow: 0-No glabella lines
|
2 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- USJ-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abobotulinum toxin A
-
Fundació Institut de Recerca de l'Hospital de la...Not yet recruitingMovement Disorders | Spasticity, Muscle | Stroke SequelaeSpain
-
Detroit Clinical Research CenterIpsenUnknownTourette Syndrome | Chronic Vocal TicUnited States
-
David M. SimpsonIpsenUnknown
-
Northwestern UniversityActive, not recruiting
-
Pôle Saint HélierCompleted
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Instituto de Oftalmología Fundación Conde de ValencianaCompletedRejuvenation | Face | Skin FoldMexico
-
Walter Reed Army Medical CenterUnknown
-
The Hospital of VestfoldSouth-Eastern Norway Regional Health AuthorityCompletedOveractive BladderNorway
-
Corfu Headache ClinicCompleted